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• Experience with the use of Orthoclone OKT3 monoclonal antibody for the treatment 01 acute cellular rejection 
in a series of 130 human orthotopic liver transplantations is reviewed. Treatment was highly effective in reversing 
rejection, in reducing the rate of retransplantation, and in lowering patient mortality. OKT3 was also useful lor 
cyclosporine sparing in patients with poor renal function, hypertension, or eNS toxicity. There was a significant 
incidence of opportunistic infection associated with the use of OKT3. 
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Ol'OE-YEAR SURYIY.O\L after liver transplan-
tation with conventional azathioprine high-
dose steroid therapy was only 32 % in the Denver 
series. This therapy was replaced by cyclosporine 
low-dose prednisone in the Denver-Pittsburgh 
liver transplant series 10 1980 and I-year graft sur-
vival subsequently improved to 70%.1 However. 
apprO'(imately 20% of the patients who have un-
dergone liver transplantation in Pittsburgh have 
required at least one more graft and over half of 
these retransplanr:ltions have been for irreversible 
allograft reJectIon. I: 
Polyclonal antllymphocyte agents (ALG) were 
,ntroduced into clinical practice by Stanl et aP 
These agents were effective but clinical use ""as 
limited by toxicity. allergenicity. and the highly 
variable biological 3ctivity of ALG preparations. 
Cosimi et al conducted the first successful 
clinical trials \I, ith Orthoclone OKT3 mouse anti-
human T (ell monoclonal 3ntibody <Ortho Phar-
maceuticals. Raritan. ~1F in renal transplanta-
tion.· s Encour3ged by these results. In po~ember 
1984 we began e\perimental use of Orthodone 
OKT3 for the treatment of acute cellular rejection 
in both cadaver kidney 3nd liver transplant recipi-
ents. The results of this e.'(perience have been pre-
viously publi:,hed. 6I \Ve here review our expe-
rience with OKT3 in liver transplantation. 
METHODS AND MATERIALS 
Case .""areriaJ 
Eighleen II'o:r lransplJnI reClpl~nls wIth biupsy prov~n aCUle 
,ellula! rC)e.:lwn "'erc Induded lR an millal randomIZed tnal of 
,terolds ,. OKT3. Because 01 f~ ImprcSSlve respon~ to OKT3 
IT ~ble II. the randumlzcd Ina! w:l5 abanduned ~fter Ihis short 
senes md re~ul;olr Irealmc:nl with Onhuclone OKT3 of all pa-
lIents lAo ,th ,lerOid re,,,l.lnl or early g~l!re>>fDc I.'cllular rCJec· 
lion ... as lR,lltUlo:d. 
Belween '1o'ember 1984 Jnd December 1985 130 liver reo 
"ipf~nts were trelled IAollh OKT3. ~1ean age of the pauents w:l5 
~UKS ~f!ar; and 57 "l: ",ere iemales. Donor·recipienl ABO blood 
group .:ompallbdity was observed whenever possible. but Iym-
phoc~Dloto~ic anubody .:rossmalching and HLA typing were 
donI! retrospecllvely and played no role in recipienl seleclion. 
Result.> ",ue compared wllh a hlSlorical conlrol series oi 237 
patients tran,planled under .:yclosponnc low·dose ,Ierolds with 
,Ieroid therapy or pol~donal ALG for trealmenl of Jl'Ule reJee-
lion. 
Cyc/osporine 
An or:!l dose 0f c~closponne I \7.5 mg'kgl was admimslered 
five 10 pl~ h0urs prellperalJ'.:ly \10 hen posslbl~ Postoperaln d~K 
palienls received intrJvenous IIV) cyclosponnc E~ mg'kgJ 1\100 
to Ihree limes per day. Oral Jdministrallon was begun :l5 soon 
as gJStroinrcstlnal (GIl tract function permined. al a dos< of 
17.5 mg 19 10 t\loO diVided Joses. IV .1nd ural JdmInI,lra{!On 
were .:onllnued unl1l sl.lble liver funclion and oral absorp!ion 
"'ere ublalned. [V JJmlOlstrallon was then tapereJ. Bluod 
kvels were mOMored da.dy uSing a "'hole blood radiOimmu-
noassay m<thod Jnd "'ere malllall~d 10 the 700 10 1.000 ng' 
mL range. renal !un.:uon perm'!!lng 
Corticostaoids 
SterOlJ, "'ere .1dmlnl>lereJ .1, In ;OIt1al bolus of 1.000 mg 
m<th~ Iprednlsolune iollo"-ed b~ a Ilve·day burst b<:glnnlng al 
~ll mg d In dlv,Jed dose:, Jnd reJuced b~ -lO mg d unlll " 
Fr,'m Ih" O"I'(1r1mt:nt . '1 pur~EDrvK ['nll(,rHf' H,.,,/rh (tTl/a of 
mlffsbur~hK ['n/l't'rSl'" v1 Pimbur/(h. (111d Iht' ~"futlns K~gm""s· 
rralltln .\1"Ji<'tl/ ernTa. mfff>bur~h 
puppvn~g b\' Rt'St!urt'h Pr''J''CI GrUnT .Vo. ',,1.1·29961 from 
rh~ 'vrJli.Jllal {ItSltIUIf!S of Hf!tlilh. Bf!rht!sriD .. \1D. L.'d. 's th~ 
rt'npit'n( ,1' u (,.nT<,nnltll F .. I1" • ..,h.p from tht' .\1 .. J'('(11 R,,· 
D~flnh CounCIl of CrJIILIJ<J. 
CmSt'fI5UJ emffr.-nO! on Jfono,'/unl1l ~ntrbIIgi<Is '" TrUIIS' 
plcJIIlQ(iofi >f'CflJored bv fh~ \'olwnul K,Jnn F"ullLial/o". 
Swusdak .-tZ. g"II~ 26-17. 1987. 
~dguss upnnT Tt'qul!slS /() Rvbt'" O. GorJon.'dO. o"pcn· 
mt'nl of sKKI~tDrvK ['IInUlin of Pirrsbur!(h School uf .'d"dldnl!. 
J6()1 Fi"h K~I~K mifEsbuD~hK P.4 15213. 
,; 1988 b\· rh, Vllllon ... / KiJfI<'\' F,'undmiun. {"e 
02 n·flJ86,S8,·/IIr.·IJV/5SJ.lXJIO 
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Table 1. Initial Randomized Trial 
Comparing High-DoN Steroids to 
Orthoclone OKT3 for the Treatment of 
Biopsy Proven Acute Cellular Rejection 
No Reversai 
Rescue 
Neeoed 
Rescue 
Successful 
OKT3 
SterOids 
7 
1 1 
6 
4 7 6n 
The tnal was abandoned after only 18 patients because 
of the obVIOUS supenonly of Orthoclone OKT3 
maintenance do~c of ~l mg,d .... a~ rea'hed. aElFKe~ were appro-
pnatel~ redu~ed for pediatriC reClplent~K If rejecton wa~ su~­
peeted. the 1.000 m~ meth~ IprednIsolone helu; and five-da) 
burst of steroIds .... ere repeated. H0v.ever. if there .... as n(\ reo 
spon~ to steroid, or In the case of severe. early re.le'lIon. the 
sterotd therapv was aboned and therapy v. nh Onhoclone 
OKD hegun 
MeThod of OKT3 AdminiSTraTion 
Onhoclone 0"T3 was administered a .. a smgle da,ly 5 m~ TV 
push mer t .... " to fl\e minutes Smaller children received ~KR 
m~ Premedlcallon Included 50 mg IV diphenhydramine and 
500 mg tf' 1.000 mg hydrocom.,0ne admlOl"ered one hour he· 
fore admmf~tratlon of the first tWf' doses of lhq~K Treatment 
.... a, wntmued for ten t(\ 14 days All patIents .... ere careful" 
ob~qy cd for de\elf'pment of senous reaction; to the drug but 
routine placement In an ICC en\Ironment for admmhtrall0n of 
OKT3 .... as nOl necessary. 
0"T3 level; .... ere measured us 109 an ellI) me-hnked tm· 
munosorbent assay (ELISA) technique and sho .... ed an excess of 
OKT3 throughout therapy The deHlopment of anll-munne 
antIbodies In recipIents of OKT3 .... a<. also monitored in most 
patients Result ... of the~ studies have been prevlousl) re-
poned." 
Analysis of Results 
T(\ analyze the results of treat men I. patfen~ .... ere diVided Into 
three groups group I. treatment .... ith 0"T3 started .... ,thln nine 
daF~ (\f transplantatIOn. group 2. treatment .... lth OK13 staned 
bet .... een ten and 90 day s of transplantatIOn: and group 3. treat-
men! .... lth OKT3 5.taned more than 90 days after transpianta-
lion 
Group I patlenb .... ere patlent~ .... ,m poor earl> graft funcuon 
tl~hemlC IOJUr: I. poor renal fun,lIon necessltallnf cvclospor· 
lOe spann~K or. In rare Instances. pallents "'lIh earl~K aggressi\e 
cellular re)eCllOn Group ~ patfent~ .... ere thEl~ most Illel\ !Cl 
ha\e acu'e cellular relectlon. and gre'ur ~ patient' .... ere the'se 
most itDei~ to h,,\e .. ml\ed pJllern (>f acute and ,;hron" re)e,;· 
lion 
RESULTS 
oandEgmi~ed Trial 
Eighteen patients. including seven treated With 
steroids and II treated with OKT3 were entered in 
an initial randomized tnal. The results are summa-
rized in Table I. Only four of the ) I patients 
treated with sterOids responded well and six of the 
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Table 2. Results of Therapy With Orthoclone OKT3 
In Three Treatment Group, Compared With 
Historical Controls 
mer~nt Percent 
Graft P.lten, 
Pe-'cem Survival Survival 
Relfansp,antatICf' 1 Vr 6 Mo 1 Vr 
ContrOl 222 549 736 71.6 
n • 237 
Overall 15.9 644 82.9 75.1 
n .. 130 
Group 1 20.6 541 72.1 67.1 
n = 49 
Group 2 6.8 76.7 86.7 79.2 
n • 65 
Group 3 375 688 81.2 722 
n = 16 
Group' was treated zero to nine days after transplan-
tation; group 2 was treated ten to 90 days after transplan· 
tation; and group 3 was treated more than 90 days after 
transplantation. 
seven grafts that failed to respond were rescued 
with OKT3. Because of the obvious superiority of 
OKT3 in this series. we felt that further ran-
domized treatment was not justified. 
OKT3 v HislOrical Controls 
The results of treatment in the three OKT3 treat-
ment groups are compared with the historical con-
trol series in Table ~ and Fig I. The retransplanta-
tion rate in the histoncal controls was 22.2 % but 
in OKT3 group 2 was only 6.8'1c (P < .05). 
Furthermore. the I-year graft survival rate is 
higher in all three OKT3 treatment groups and is 
highest in group 2. ACTUarial survival for group 2 
patients was significantly better (P < .01) than for 
the controls (Fig I). 
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Fig 1. Actuarial graft survival in group 1 and group 
2 patients treated with Orthoclone OKT3 compared 
with historical controls treated with high dose ste-
roids and/or polyclonal ALG. Survival of group 2 
grafts is significantly better than control and group 1 
grafts (P < .01). 
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OKT3 IN LIVER TRANSPtJ.NTATlON 
Table 3. Side Effects in 72 Patients 
Treated With OKT3 
Nausea. vomiting. diarrhea 22 
Pyrexia. chills 19 
FluShing. diaphoresIs 7 
HypotenSion 6 
TaChycardia 6 
Abnormal chest scunds 6 
HypertenSion 5 
Weakness 5 
Dyspnea 4 
Edema 4 
Lightheadedness 4 
Chest pain 4 
Headache 3 
Rash 2 
Cough 2 
Anorexia 
Nearly all occurred Within the first 48 hours of adminis-
tralion and subsided with subsequent doses. None of 
Ihese patients had to be Withdrawn Irom the drug. 
Adverse Reactions and Complications 
Side effects of therapy were common but usually 
self limited and tolerable. Detailed records of 72 
consecutively treated patients were reviewed to 
assess side effects and are summarized in Table 3. 
GI side effects were the most common followed by 
fever and chills. ~one of these patients had to be 
withdrawn from the drug and there were no 
anaphylactic reactions. In fact. in our entire expe-
rience with OKT3. we have only observed one 
possible .1Oaph: lactic reaction in a patient treated 
for the third time WIth OKT3 who developed respi-
ratory distress Jnd required intubation. She 
promprly recovered Jnd was extubated within :!4 
hours. 
Infectious complications have been common. 
Leucopenia (WBC < 4.0/mml) suggestive of 
viral infection were observed in more than half of 
the patients and infections with cytomegalovirus. 
herpes virus. and pneumocystis were common and 
occasionally fatal. 
CONCLUSIONS 
Orthoclone OKT3 is a highly effective immuno-
suppressive agent for the treatment of acute cellu-
lar rejection in liver transplant recipients. It has 
been most effective when administered in the pe-
riod ten to 90 days after transplantation when al.:ute 
cellular rejection is most prone to occur. but it may 
be c:ffective \\, hen administered earlier or later if 
acute cellular rejection is a significant I.:omponent 
of graft dysfunction. 
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Orthoclone OKTJ is also an effective ag~nt 
when cyc\osporine spanng is indicated. \Ve ;'",--e 
had ~uccess using OKT3 in place of cycll~p"r . ne 
during the first 2 weeks after transplantatlon In pa-
tients unable to tolerate cyclosporine. usually ~­
cause of nephroto,lClty. or rarely because of 
severe h) ~nenslon or eNS toxicity. 
As is true of other efficacious inununosuppres-
sive agents. Orthoclone OKT3 is associated with a 
high incidence of opportunistic infection. espe-
cially with cytomegalovirus. herpes virus. and 
PneuTnOc-ystis carinii. The high infection rate we 
have e'perienced may in pan reflect our policy of 
continuing with cyclosporine therapy in most pa-
tients treated for acute cellular rejection with Or-
thoclone OKT3. Perhaps it is safer and equally 
eificacious to reduce or discontinue cyc\osporine 
therapy during the initial phase of OKT3 therapy 
and return to therapeutic treatment with cyc\ospor-
ine during the last several days of OKT3 adminis-
tration. We have not seen a high rate of rebound 
rejection after OKT3 in patients who are at thera-
peutic levels of cyc\osporine on completion of 
OKT3 therapy. 
During the past 18 months we have retreated pa-
tients with OKT3 for subsequent steroid-reSistant 
acute rejection episodes with success provided the 
patients have not developed antimurine antibodies 
after their first course of therapy. Ex.cept to the one 
case cited above, serious adverse reactions with 
retreatment have not been a significant problem. It 
is our impression that OKT3 can be effectivel .... 
reused in many patients and that the drug should 
not be .... ithheld when indicated to save it for possi-
ble use at some later and tndefinite time. 
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Fig 2. Current protocol for UI. of Orthoclone 
OKT3 In the management of liver transplant recipi-
entl. Prophylactic UN of OKT3 In high-risk patients 
nMdI also to be considered. 
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Our current protocol for u ... e ()f Orth()c1one 
OKT3 i .. summarized in FI£ 2. Orthoclonc OKT3 
ma~ al\o have a role a ... a prophylactic a~ent in 
p<lticnt\ wllh a hislory ()f hi~h il11munEFreacliyit~K 
GORDON ET AL 
such a ... palK'n!'- undcr~EFm~ retran~plantation for 
rejection of a prC\IOU\ ~raftK Further !'tudy of this 
application 01 Onhlll.:II.IOC OKT3 i ... needed. 
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